BEAM
Closed
Beam Therapeutics inc
17.53
+0.52 (+3.06%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 17.01
Day's Range: 16.59 - 18.2335
Send
sign up or login to leave a comment!
When Written:
30.62
Beam Therapeutics Inc. is a biotechnology company that is focused on developing precision genetic medicines using its proprietary base editing technology. The company was founded in 2017 and is headquartered in Cambridge, Massachusetts.
Beam's base editing technology is designed to enable precise and efficient editing of individual DNA bases, which could potentially be used to treat a wide range of genetic diseases. The company is currently developing a pipeline of base editing therapies, including treatments for sickle cell disease, beta-thalassemia, and other genetic disorders.
Beam is backed by a number of prominent investors, including F-Prime Capital, Redmile Group, and Arch Venture Partners. The company went public in February 2020 and is listed on the Nasdaq Global Select Market under the ticker symbol "BEAM."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Beam's base editing technology is designed to enable precise and efficient editing of individual DNA bases, which could potentially be used to treat a wide range of genetic diseases. The company is currently developing a pipeline of base editing therapies, including treatments for sickle cell disease, beta-thalassemia, and other genetic disorders.
Beam is backed by a number of prominent investors, including F-Prime Capital, Redmile Group, and Arch Venture Partners. The company went public in February 2020 and is listed on the Nasdaq Global Select Market under the ticker symbol "BEAM."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








